

# TABLE OF CONTENTS

**PEDIATRICS . . . . . 1-3**

*Sepsis and Meningitis; Respiratory Syncytial Virus Infection; Otitis Media; Immunizations; Pediatric Seizure Disorders; Attention-Deficit/Hyperactivity Disorder*

**GERIATRICS . . . . . 1-39**

*Principles to Promote Optimal Medication Use in Older People; Dementia; Behavioral Symptoms of Dementia; Urinary Incontinence; Benign Prostatic Hypertrophy; Osteoarthritis; Rheumatoid Arthritis*

**NEUROLOGY . . . . . 1-83**

*Epilepsy; Ischemic Stroke; Parkinson Disease; Headache; Multiple Sclerosis*

**GENERAL PSYCHIATRY . . . . . 1-145**

*Depression; Bipolar Disorder; Schizophrenia; Anxiety Disorders; Insomnia; Substance Use Disorders*

**ENDOCRINE AND METABOLIC DISORDERS . . . . . 1-203**

*Thyroid Disorders; Pituitary Gland Disorders; Adrenal Gland Disorders; Obesity; Polycystic Ovary Syndrome; Diabetes Mellitus and Insipidus; Treatment of DM Complications; Other Diabetes Medication Issues*

**NEPHROLOGY . . . . . 1-261**

*Acute Kidney Injury (AKI) or Acute Renal Failure (ARF); Drug-Induced Kidney Damage; Chronic Kidney Disease; Renal Replacement Therapy (RRT); Managing the Complications of Chronic Kidney Disease; Dosage Adjustments in Kidney Disease*

**FLUIDS, ELECTROLYTES, AND NUTRITION . . . . . 1-307**

*Fluid Management; Osmolality; Hypertonic Saline; Hypotonic Intravenous Fluids; Hyponatremia and Hypo-osmolal States; Hypernatremia and Hyperosmolal States; Disorders of K<sup>+</sup>; Disorders of Magnesium Homeostasis; Disorders of Phosphorus Homeostasis; Disorders of Calcium Homeostasis; Enteral Nutrition; Parenteral Nutrition*

**BIOSTATISTICS: A REFRESHER . . . . . 1-357**

*Introduction to Statistics; Types of Variables and Data; Types of Statistics; Population Distributions; Confidence Intervals; Hypothesis Testing; Statistical Tests; Decision Errors; Correlation and Regression; Survival Analysis; Selected Representative Statistical Tests*

**STUDY DESIGNS: FUNDAMENTALS, INTERPRETATION, AND RESEARCH TOPICS . . . . . 1-381**

*Various Issues in Study Design; Case Reports and Case Series; Observational Study Designs; Incidence, Prevalence, Relative Risks or Risk Ratios, and Odds Ratios; Randomized Controlled Trial Design; Other Issues to Consider in Controlled Trials; Controlled Clinical Trials: Analyzing Clinical Trials; Systematic Review and Meta-analysis; Summary Measures of Effect; Reporting Guidelines for Clinical Studies; Pharmacoeconomic Studies; Sensitivity/Specificity/Predictive Values; Institutional Review Board/Human Subjects' Research; Professional Writing: The Publication Process*

**MEN'S AND WOMEN'S HEALTH . . . . . 1-415**

*Hormone Therapy/Menopause; Osteoporosis; Drugs in Pregnancy; Drugs in Lactation; Complications in Pregnancy; Contraception; Menstrual Disorders; Infertility; Sexually Transmitted Infections; Prostatic Infections; Sexual Dysfunction*

**CRITICAL CARE. . . . .1-499**

*Interpretation of Hemodynamic Parameters; Treatment of Shock; Interpretation of Acid-Base Disturbances; Acute Respiratory Failure; Cardiac Arrest; Pain, Agitation, Delirium, and Neuromuscular Blockade; Glucose Control; Preventing Stress Ulcers; Pharmacologic Therapy for Preventing Venous Thromboembolism; Preventing Ventilator-Associated Pneumonia; Nutritional Support in Critically Ill Patients*

**PHARMACOKINETICS: A REFRESHER . . . . . 1-557**

*Basic Pharmacokinetic Relationships; Absorption; Distribution; Clearance; Nonlinear Pharmacokinetics; Noncompartmental Pharmacokinetics; Data Collection and Analysis; Pharmacokinetics in Renal Disease; Pharmacodynamics*

**PULMONARY DISORDERS, GOUT, AND ADULT IMMUNIZATIONS. . . . . 1-595**

*Asthma; Chronic Obstructive Pulmonary Disease; Gout; Adult Immunizations*

## TABLE OF CONTENTS

### **CARDIOLOGY I .....2-3**

*Acute Coronary Syndromes; Acute Decompensated Heart Failure; Acute Arrhythmias/Advanced Cardiac Life Support; Hypertensive Emergency; Pulmonary Arterial Hypertension*

### **CARDIOLOGY II.....2-65**

*Heart Failure; Atrial Fibrillation; Hypertension; Dyslipidemia; CHD and Chronic Stable Angina*

### **ONCOLOGY SUPPORTIVE CARE ..... 2-133**

*Antiemetics; Pain Management; Treatment of Febrile Neutropenia; Use of CSFs in Neutropenia and Febrile Neutropenia; Thrombocytopenia; Anemia and Fatigue; Chemoprotectants; Oncology Emergencies; Miscellaneous Antineoplastic Pharmacotherapy*

### **GASTROINTESTINAL DISORDERS..... 2-175**

*Gastroesophageal Reflux Disease (GERD); Peptic Ulcer Disease; Upper GI Bleeding; Inflammatory Bowel Disease (IBD); Complications of Chronic Liver Disease; Viral Hepatitis; Nausea and Vomiting; Pancreatitis; Diarrhea; Constipation; Irritable Bowel Syndrome*

### **INFECTIOUS DISEASES ..... 2-261**

*Respiratory Tract Infections; Urinary Tract Infections; Skin and Soft Tissue Infections; Osteomyelitis; Central Nervous System Infections; Endocarditis; Intra-abdominal Infections; Clostridium difficile Infection; Medical/Surgical Prophylaxis*

### **HIV/INFECTIOUS DISEASES ..... 2-313**

*Human Immunodeficiency Virus; Opportunistic Infections in Patients with HIV; Tuberculosis; Antifungal Therapy*

### **POLICY, PRACTICE, AND REGULATORY ISSUES ..... 2-361**

*Institutional Medication Use Policy Considerations; Congressional Overview, Committees with Jurisdiction over Health-Related Policy, and the Legislative Process; U.S. Government Departments and Agencies with Primary Regulatory Impact on the Practice of Pharmacy; Accrediting Organizations and Quality Improvement Efforts; the U.S. Food and Drug Administration and the Prescription Drug Approval Process; Institutional Review Board Implications for Clinical Practice and Research; Investigational Drug Service*

### **ECONOMIC AND PATIENT-REPORTED OUTCOMES ASSESSMENT..... 2-403**

*Outcomes; Cost; Perspective; Components of Pharmacoeconomic Analyses; Pharmacoeconomic Evaluations; Patient-Reported Outcomes*

## **ADDITIONAL RESOURCES**

### **PRACTICES AND PROCESSES OF CARE/ORGANIZATIONAL AGREEMENTS/ SPECIAL ISSUES IN PHARMACY PRACTICE . . . . . 2-447**

*Scopes of Practice; Pharmaceutical Care; Medication Therapy Management; Comprehensive Medication Management; Collaborative Drug Therapy Management; Credentialing and Privileging; Pharmacists' Patient Care Process; Transitions of Care; Medication Reconciliation; Immunizations; Point-of-Care Testing; Patient Assistance; Medication Safety; Pharmacy and Therapeutics Committees and Formulary Management; Medicare Part D*

### **COMMUNICATION STRATEGIES IN PHARMACY . . . . . 2-519**

*Communicating Verbally with Patients and Caregivers; Selecting Written Patient Educational Materials; Alternative Methods of Communicating with Patients; Communicating with Other Health Care Professionals; Documenting in the Medical Record; Opportunities for Patient Advocacy Outside the Health Care System*

### **PRINCIPLES AND METHODS OF EDUCATING HEALTH CARE PROFESSIONALS . . . . 2-565**

*Evidence Supporting Teaching, Precepting, and Learning; Current Educational Frameworks and Guiding Philosophies; Designing Instruction to Achieve Learning Outcomes; Additional Thoughts on Role Modeling and Mentoring; Knowledge and Skill Assessment Techniques*

### **MANAGING A CLINICAL PRACTICE . . . . . 2-595**

*General Ongoing Management; Determining How You Will Communicate; Establish a Standard Process for Documentation; Measuring the Quality of Your Program; Ensuring the Continued Competency of Your Staff; Reimbursement for Pharmacist Services in the Ambulatory Setting; Sustaining Your Practice for the Future*

### **DRUG INFORMATION RESOURCES AND LITERATURE RETRIEVAL . . . . . 2-653**

*Overview of Drug Information Resources; Internet Sources of DI; Evaluating DI Resources; Accessing Quality DI Resources; Specific DI Resources*

### **THE BOARD OF PHARMACY SPECIALTIES "2017 RECERTIFICATION GUIDE" . . . . . 2-681**

*Printed courtesy of the Board of Pharmacy Specialties*